Author

Neils Halama

Observed name: N. Halama

Institutions: University Hospital Heidelberg, National Center for Tumor Diseases

Observed institutions: University Hospital Heidelberg, National Center for Tumor Diseases

OpenAlex ID: A5067809873

First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors.

2015 · Devalingam Mahalingam, Manish R. Patel, et al. · Journal of Clinical Oncology · 9

S282: a Randomized Controlled Clinical Trial Demonstrates That Plasma From Convalescent and Vaccinated Donors Improves Outcome of Covid-19 in Patients With Hematological Disease, Cancer or Immunosuppression

2022 · C. Müller-Tidow, M. Janssen, et al. · HemaSphere · 2

Works count: 2

Citation count: 11

H-index: 2

I10-index: